Lack of an association between SCFD1 rs10139154 polymorphism and amyotrophic lateral sclerosis.


Journal

Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 12 01 2022
accepted: 15 02 2022
entrez: 2 3 2022
pubmed: 3 3 2022
medline: 8 4 2022
Statut: ppublish

Résumé

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. Through a genome‑wide association study (GWAS), the Sec1 family domain‑containing protein 1 (SCFD1) rs10139154 variant at 14q12 has emerged as a risk factor gene for ALS. Moreover, it has been reported to influence the age at onset (AAO) of patients with ALS. The aim of the present study was to assess the association of the SCFD1 rs10139154 polymorphism with the risk of developing ALS. For this purpose, 155 patients with sporadic ALS and 155 healthy controls were genotyped for the SCFD1 rs10139154. The effect of the SCFD1 rs10139154 polymorphism was then examined on the following parameters: i) The risk of developing ALS; ii) the AAO of ALS; iii) the site of ALS onset (patients with bulbar onset ALS vs. healthy controls; and patients with limb onset ALS vs. healthy controls); and iv) the AAO of ALS onset with subgroup analyses based on the site of onset (bulbar and limb, crude and adjusted for sex). The analysis of all the outcomes was performed assuming five genetic models. Crude and adjusted analyses were applied. The threshold for statistical significance was set at 0.05. The results revealed no association between SCFD1 rs10139154 and any of the examined phenotypes in any of the models examined. On the whole, based on the findings of the present study, SCFD1 rs10139154 does not appear to play a determining role in the risk of developing ALS.

Identifiants

pubmed: 35234271
doi: 10.3892/mmr.2022.12662
pii: 146
pmc: PMC8915390
doi:
pii:

Substances chimiques

Adaptor Proteins, Vesicular Transport 0
SCFD1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Neurobiol Dis. 2005 Feb;18(1):143-51
pubmed: 15649705
Mayo Clin Proc. 2018 Nov;93(11):1617-1628
pubmed: 30401437
Neurol Clin Pract. 2018 Oct;8(5):437-444
pubmed: 30564498
Front Neurosci. 2019 Dec 06;13:1310
pubmed: 31866818
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
J Mol Neurosci. 2019 Oct;69(2):343-350
pubmed: 31267315
Mol Biol Rep. 2021 Mar;48(3):2601-2610
pubmed: 33826063
Bioinformatics. 2006 Aug 1;22(15):1928-9
pubmed: 16720584
Amyotroph Lateral Scler. 2010 Oct;11(5):439-42
pubmed: 20225930
Curr Opin Cell Biol. 2010 Aug;22(4):488-95
pubmed: 20471239
Dev Biol. 2017 Jan 1;421(1):8-15
pubmed: 27851892
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):413-418
pubmed: 29260601
Transl Neurodegener. 2016 Feb 03;5:3
pubmed: 26843957
Mol Ther. 2021 Dec 1;29(12):3345-3358
pubmed: 33839324
Neurol Sci. 2021 Jan;42(1):175-182
pubmed: 32592103
Neurol Clin. 2015 Nov;33(4):855-76
pubmed: 26515626
Nat Rev Dis Primers. 2017 Oct 05;3:17071
pubmed: 28980624
Nat Commun. 2021 Feb 17;12(1):1107
pubmed: 33597541
Neurol Sci. 2019 Jun;40(6):1237-1244
pubmed: 30879219
Front Neurosci. 2020 Feb 05;14:42
pubmed: 32116499
N Engl J Med. 2017 Jul 13;377(2):162-172
pubmed: 28700839
J Mol Neurosci. 2018 Dec;66(4):617-628
pubmed: 30415446
Lancet. 2017 Nov 4;390(10107):2084-2098
pubmed: 28552366
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-2
pubmed: 26121170
PLoS One. 2021 Nov 29;16(11):e0260323
pubmed: 34843548
Chest. 2019 Feb;155(2):401-408
pubmed: 29990478
Eur J Neurol. 2020 Oct;27(10):1918-1929
pubmed: 32526057
J Mol Neurosci. 2020 Jun;70(6):851-860
pubmed: 32088842
Nat Genet. 2016 Sep;48(9):1043-8
pubmed: 27455348
Medicina (Kaunas). 2021 Dec 07;57(12):
pubmed: 34946282
J Neurol Sci. 2019 Apr 15;399:217-226
pubmed: 30870681
Brain Commun. 2021 Oct 07;3(4):fcab236
pubmed: 34708205
Neuromolecular Med. 2019 Mar;21(1):68-74
pubmed: 30519954
Int J Epidemiol. 2017 Feb 1;46(1):57-74
pubmed: 27185810
Nat Rev Neurol. 2021 Feb;17(2):104-118
pubmed: 33340024
Neurology. 2020 May 12;94(19):e2005-e2013
pubmed: 32277059
Front Neurol. 2021 Mar 29;12:596006
pubmed: 33854469
Cold Spring Harb Perspect Med. 2018 May 01;8(5):
pubmed: 28270533
Environ Int. 2018 Jul;116:122-135
pubmed: 29677557

Auteurs

Vasileios Siokas (V)

Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.

Athina-Maria Aloizou (AM)

Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.

Ioannis Liampas (I)

Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.

Christos Bakirtzis (C)

B' Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.

Grigorios Nasios (G)

Department of Speech and Language Therapy, University of Ioannina, 45500 Ioannina, Greece.

Konstantinos Paterakis (K)

Department of Neurosurgery, University Hospital of Larissa, Medical School, University of Thessaly, 41100 Larissa, Greece.

Markos Sgantzos (M)

Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.

Dimitrios P Bogdanos (DP)

Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.

Demetrios A Spandidos (DA)

Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Aristidis Tsatsakis (A)

Laboratory of Toxicology, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Panayiotis D Mitsias (PD)

Department of Neurology, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Efthimios Dardiotis (E)

Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH